22nd week of 2014 patent applcation highlights part 46 |
Patent application number | Title | Published |
20140148430 | IMIDAZOPYRIDINES SYK INHIBITORS - Certain imidazopyridines (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample. | 2014-05-29 |
20140148431 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed. | 2014-05-29 |
20140148432 | Compounds for the Treatment of Neurological Disorders - Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of certain neurologic disorders, including disorders related to NMDA receptor activation, including neuropsychiatric disorders, neurodegenerative diorders and other neurologic diseases, disorders and conditions including stroke, brain injury, epilepsy, neuropsychiatric disorders, mood disorders, chronic pain and related conditions. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: | 2014-05-29 |
20140148433 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF - The present application relates to novel bicyclic azaheterocycles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders. | 2014-05-29 |
20140148434 | PYRAZOLOPYRIDINE KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2014-05-29 |
20140148435 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS - Azetidine and piperidine compounds of formula (I): | 2014-05-29 |
20140148436 | AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: | 2014-05-29 |
20140148437 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS - This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders. | 2014-05-29 |
20140148438 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS - There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof. | 2014-05-29 |
20140148439 | USE OF ANTIOXIDANTS FOR THE TREATMENT OF COGNITIVE AND BEHAVIOURAL DISORDERS IN INDIVIDUALS WITH FRAGILE X SYNDROME - The invention relates to the use of antioxidants such as, ascorbic acid (Vitamin C), Tocopherol (Vitamin E), vitamin A and polyphenols, for the treatment of cognitive and behavioural disorders in patients with Fragile X syndrome. Specifically, the invention relates to the use of said antioxidants in a pre-determined concentration in a therapeutic doses, in order to obtain the greatest amount of antioxidants possible in all the tissues of the organism, so as to eliminate the excess free radicals produced in the cells and to treat the aforementioned cognitive and behavioural disorders in patients with Fragile X syndrome. | 2014-05-29 |
20140148440 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS - The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H | 2014-05-29 |
20140148441 | 6-((S)-1--ETHYL)-3H-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST - A TARP γ8 dependant AMPA receptor antagonist of the formula: | 2014-05-29 |
20140148442 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS - Salts of the 5-HT | 2014-05-29 |
20140148443 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX - Disclosed are compounds of Formula I | 2014-05-29 |
20140148444 | METHODS OF USING PYRUVATE KINASE ACTIVATORS - Described herein are compounds that activate pyruvate kinase, for use in a method for increasing lifetime of the red blood cells, for regulating 2,3-diphosphoglycerate levels in blood and for treating sickle cell anemia. | 2014-05-29 |
20140148445 | Methods of Detecting Amyotrophic Lateral Sclerosis (ALS) - In one aspect, the invention is directed to a method of identifying an individual that has amyotrophic lateral sclerosis (ALS) or is at risk of developing ALS comprising detecting one or more alterations in a profilin 1 (PFN1) sequence of an individual in need thereof compared to a wild type profilin sequence. In another aspect, the invention is directed to a method of identifying an individual that has amyotrophic lateral sclerosis (ALS) or is at risk of developing ALS comprising selectively sequencing a profilin 1 (PFN1) sequence of an individual in need thereof; and detecting one or more alterations in the PFN1 sequence of the individual. If the one or more alterations are detected then the individual has ALS. | 2014-05-29 |
20140148446 | COMPOUNDS THAT ENABLE ALTERNATIVE MITOCHONDRIAL ELECTRON TRANSFER - The present invention relates to novel compositions and uses thereof as antioxidants and/or neuroprotective agents for the treatment of medical conditions associated with oxidative stress and/or neural damage, such as, for example, neurological diseases, disorders and trauma, and hence in the treatment of CNS-associated diseases, disorders and trauma. | 2014-05-29 |
20140148447 | AGENT FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF HERPES INFECTIONS - The invention relates to an agent for the prophylactic and therapeutic treatment of virus infections, said agent containing piroxicam in a carrier substance. | 2014-05-29 |
20140148448 | INHIBITORS OF C-FMS KINASE - The invention is directed to compounds of Formula I: | 2014-05-29 |
20140148449 | HIGHLY LOADED AMORPHOUS EFAVIRENZ COMPOSITION AND PROCESS FOR PREPARING THE SAME - A stable and high loading ternary solid dispersion composition comprising (a) about 50% wt. to about 90% wt. of amorphous Efavirenz; (b) about 10% wt. to about 50% wt. of polyvinyl pyrrolidone (PVP), a first polymer; (c) about 1% wt. to about 30% wt. of a water-soluble second polymer; and (d) optionally about 0.1% wt. to about 50% wt. of at least one pharmaceutically acceptable excipient. Also discloses a high loading ternary composition comprising (a) a solid dispersion composition comprising (i) about 50% wt. to about 90% wt. of amorphous Efavirenz; (ii) about 10% wt. to about 50% wt. of polyvinyl pyrrolidone, a first polymer; (b) about 1% wt. to about 30% wt. of a water-soluble second polymer blended with solid dispersion of composition of (a); and (c) optionally about 0.1% wt. to about 50% wt. of at least one pharmaceutically acceptable excipient. Additionally discloses a method for preparing solid dosage forms comprising (i) amorphous Efavirenz and (ii) polyvinyl pyrrolidone (PVP), a first polymer; (iii) a water-soluble second polymer; and (iv) optionally, at least one pharmaceutical excipients. | 2014-05-29 |
20140148450 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS - The present invention is concerned with novel substituted indole derivatives of Formula (I) wherein R | 2014-05-29 |
20140148451 | Autophagy Inhibitors - The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors. | 2014-05-29 |
20140148452 | MORPHOLINO COMPOUNDS, USES AND METHODS - The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R | 2014-05-29 |
20140148453 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS - Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R | 2014-05-29 |
20140148454 | SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS - The invention relates to amino-arylcarboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders. | 2014-05-29 |
20140148455 | PRESERVATIVE FREE BIMATOPROST AND TIMOLOL SOLUTIONS - The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma. | 2014-05-29 |
20140148456 | PRESERVATIVE FREE BRIMONIDINE AND TIMOLOL SOLUTIONS - The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma. | 2014-05-29 |
20140148457 | Thiazole derivatives - Compounds of the formula I | 2014-05-29 |
20140148458 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS - The present invention relates to a heterocyclic compound of the general formula (I) and their use and preparation, methods of making the compounds, compositions containing at least one of said compounds, and methods of treatment using at least one compound. In particular, compounds of the general formula (I) are useful for inhibiting glycogen synthase kinase 3 (GSK-3), | 2014-05-29 |
20140148459 | MATRIX METALLOPROTEINASE INHIBITORS - This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and pounds. | 2014-05-29 |
20140148460 | THERAPEUTIC COMPOSITIONS - The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved. | 2014-05-29 |
20140148461 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A - The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. | 2014-05-29 |
20140148462 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS - The present invention relates to compounds of general formula I, | 2014-05-29 |
20140148463 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I) in which D, R | 2014-05-29 |
20140148464 | SALT FORMS OF FATTY ACIDS FOR THE TREATMENT OF DRY EYE - Provided herein are compositions for the treatment of dry eye, comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a fatty acid salt, and methods of use thereof. | 2014-05-29 |
20140148465 | Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine - The invention describes methods and compositions for alleviating medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical compound that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction, wherein D-cycloserine is the pharmaceutical compound that enhances learning. Representative afflictions include pain, mood disorders, anxiety disorders including performance anxiety, insomnia, female sexual dysfunction, chronic fatigue, autism spectrum disorders, fibromyalgia, and attention deficit-hyperactivity disorder. | 2014-05-29 |
20140148466 | TRPA1 Receptor Antagonist - A compound of Formula (I), pharmaceutically acceptable salts thereof, enantiomers, or mixtures thereof: pharmaceutical compositions containing said compounds, enantiomers or mixtures, processes for making said compounds, enantiomers or mixtures, the use of said compounds, enantiomers or mixtures, and medicaments containing the same for treatment of pain and other conditions, and methods of treating pain and other conditions with the same. | 2014-05-29 |
20140148467 | Carboxamide Compounds and Methods for Using the Same - Disclosed are carboxamide compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure | 2014-05-29 |
20140148468 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS - The invention relates to specific carboxamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments. | 2014-05-29 |
20140148469 | USE OF FORM-I CRYSTAL OF 2--N-(METHYLSULFONYL)ACETAMIDE - A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (hereinafter referred to as “compound A”). A Form-I crystal of compound A shows diffraction peaks at 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees in the powder X-ray diffraction spectrum thereof. A Form-II crystal of compound A shows diffraction peaks at 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees in the powder X-ray diffraction spectrum thereof. A Form-III crystal of compound A shows diffraction peaks at 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees and 23.5 degrees in the powder X-ray diffraction spectrum thereof. | 2014-05-29 |
20140148470 | PYRIMIDINE COMPOUNDS FOR TREATING HAIRLOSS - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof for use in the treatment or prevention of hairloss, | 2014-05-29 |
20140148471 | Heterocyclic Compounds as Pesticides - The present application relates to novel heterocyclic compounds, to the use thereof for controlling animal pests, which include arthropods and especially insects, and to processes for preparing the novel compounds. | 2014-05-29 |
20140148472 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF - Disclosed are compounds able to modulate the activity of the GPR17 receptor in a highly specific way, which are useful in the treatment and diagnosis of diseases or dysfunctions involving the activation of said receptor. In particular, the compounds according to the invention can be used for neuroprotective and/or reparatory purposes, in cerebral, cardiac and renal ischaemia, in cerebral trauma, in chronic neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), and in demyelinating diseases such as multiple sclerosis. | 2014-05-29 |
20140148473 | USE OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE IN TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES - Provided herein are methods of using compounds and compositions for modulating lymphocytic activity, including activity of B cells and/or T cells, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein. | 2014-05-29 |
20140148474 | AMINOPYRIMIDINES AS SYK INHIBITORS - The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis and cancer. | 2014-05-29 |
20140148475 | 4-HYDROXYBENZOMORPHANS - 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. A compound of formula | 2014-05-29 |
20140148476 | METHODS FOR TREATING OBESITY AND DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL - The disclosure relates to methods for treating hyperlipidemia in a mammal. The present disclosure also relates to methods for treating and/or controlling obesity in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and a DGAT inhibitor (for example, JTT-553 or PF-04415060). Co-administration of the MTP inhibitor with the DGAT inhibitor produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and/or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit. | 2014-05-29 |
20140148477 | ANIMAL ECTOPARASITE-CONTROLLING AGENT AND METHOD FOR PREVENTING OR TREATING INFECTION IN ANIMALS CAUSED BY PARASITES BY USING THE CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent and a method for preventing or treating infection in animals caused by parasites by using the controlling agent. An animal ectoparasite-controlling agent exhibiting excellent insecticidal activity, and a method for preventing or treating infection in animals caused by parasites by using the controlling agent are obtained by using a compound having a pyrazole ring at the 4-position of the piperidine ring as an active ingredient. | 2014-05-29 |
20140148478 | HETEROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS - The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders. | 2014-05-29 |
20140148479 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof - (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition. | 2014-05-29 |
20140148480 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES - A compound of formula (I-1) | 2014-05-29 |
20140148481 | PITAVASTATIN CALCIUM AND PROCESS FOR ITS PREPARATION - The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions. | 2014-05-29 |
20140148482 | METHOD FOR SCREENING ANTI-CANCER DRUGS AND METHOD OF CANCER TREATMENT - The present application provides a method for screening compounds for cancer treatment comprising treating cancer cells with a candidate compound for sufficient time for detectable expression of a gene selected from GADD45 family; and detecting the level of expression of the gene as compared to the level of expression in the absence of the candidate compound; wherein an increased level of expression in the presence of the candidate compound as compared to expression in the absence of the candidate compound indicates that the candidate compound acts as an inhibitor of the cancer cells. In some embodiments, the method can be used for screening compounds for treatment of sorafenib-resistant hepatocellular carcinoma. The present application further provides a method for treating hepatocellular carcinoma comprising administering to a subject having hepatocellular carcinoma a therapeutic effective amount of an agonist of GADD45 family. | 2014-05-29 |
20140148483 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor - The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject. | 2014-05-29 |
20140148484 | PYRAZOLE COMPOUNDS FOR TREATING HAIRLOSS - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof for use in the treatment or prevention of hairloss, | 2014-05-29 |
20140148485 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRANE - Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination. | 2014-05-29 |
20140148486 | SODIUM CHANNEL BLOCKER DELIVERY SYSTEM WITH SCLERAL LENS - A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed. | 2014-05-29 |
20140148487 | ANTIMICROBIAL AMPHIPHILES AND METHODS FOR THEIR USE - The present invention is directed to compositions useful for antimicrobial applications. These compositions comprise amphiphilic compounds. | 2014-05-29 |
20140148488 | Compositions and Methods for Modulating Metabolic Pathways - Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine. | 2014-05-29 |
20140148489 | 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives - The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2014-05-29 |
20140148490 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS - The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases. | 2014-05-29 |
20140148491 | Chemical Compositions And Methods For Enhancing Transdermal Delivery Of Therapeutic Agents - The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists. | 2014-05-29 |
20140148492 | BICYCLOSUBSTITUTED PYRAZOLE COMPOUNDS FOR TREATING HAIR LOSS - The present invention relates to compounds of formula (Ia) or (Ib) or pharmaceutically acceptable salts thereof for use in the treatment or prevention of hairloss, | 2014-05-29 |
20140148493 | Agricultural and Horticultural Insecticide Composition and Method for Using the Same - Provided are an agricultural and horticultural insecticide composition comprising flubendiamide and tolfenpyrad as active ingredients; and a method for using an agricultural and horticultural insecticide composition, comprising treating insect pests directly, treating crops potentially infested with the insect pests, or treating surrounding soil or cultivation medium of the crops with an effective amount of an agricultural and horticultural insecticide composition comprising flubendiamide and tolfenpyrad as active ingredients. | 2014-05-29 |
20140148494 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 2014-05-29 |
20140148495 | MONOLITHIC DRUG DELIVERY SYSTEM - An improved monolithic drug delivery dosage form releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relaxes on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate. | 2014-05-29 |
20140148496 | Therapeutic and Diagnostic Method for Ataxia-Telangiectasia - ATM kinase is shown to regulate proteasome-mediated protein turnover through suppression of the expression of the ubiquitin-like protein ISG15 (Interferon Stimulated Gene 15). Silencing of the ISG15 pathway restored both the ubiquitin and autophagy pathways, and the UV-mediated degradation of their substrates in A-T cells. The ATM kinase negatively regulates the ISG15 pathway, and the constitutively elevated ISG15 pathway induces proteinopathy in A-T cells, and in A-T patients. These findings indicate that proteasome-mediated protein degradation is impaired in A-T cells due to elevated expression of the ISG15 conjugation pathway, which contributes to progressive neurodegeneration in A-T patients. The ISG15 pathway is a new target for both detection and treatment of A-T Inhibitors if ISG15 expression can be used to inhibit or attenuate neurodegeneration in A-T patients. In addition, an inhibitor of the early phase of autophagy, 3-MA, was shown to be effective in decreasing the impaired proteasome-mediated protein degradation in A-T cells, and thus would be effective in decreasing the neurodegeneration in A-T patients. | 2014-05-29 |
20140148497 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1. | 2014-05-29 |
20140148498 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MARFAN SYNDROME AND ASSOCIATED DISORDERS - The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. | 2014-05-29 |
20140148499 | METHODS AND REAGENTS FOR EFFICIENT CONTROL OF HIV PROGRESSION - The invention relates to methods for the identification of HIV-1 infected subjects capable of controlling viral load based on the determination of the expression levels of several miRNAs. In addition, the invention also relates to methods for controlling HIV infection by using some of the differentially expressed miRNAs or polynucleotides encoding said miRNAs, as well as to compositions comprising a miRNA or a polynucleotide encoding said miRNA and an anti-HIV agent. | 2014-05-29 |
20140148500 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS - The invention concerns compositions comprising strands of polynucleotide and strands of PNA, each PNA strand comprising: (i) from 2 to 50 nucleobase subunits and (ii) one or more gamma substituents. The PNA strands are complementary to at least a portion of at least some of the polynucleotide strands, and the molar ratio of PNA strands to polynucleotide strands being at least 1:1. Certain gamma substituents are capable of effecting attachment of a PNA strand to a cell. The invention also concerns construction of nanostructure platforms and vaccines and use of the inventive compositions in inhibiting disease states in mammals. | 2014-05-29 |
20140148501 | DNA APTAMERS FOR PROMOTING REMYELINATION - Materials and methods related to using multimeric DNA aptamers to treat demyelinating diseases are provided herein. | 2014-05-29 |
20140148502 | MODIFIED POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2014-05-29 |
20140148503 | NUCLEIC ACID APTAMERS - The present invention relates to optimized aptamers and methods of using these aptamers. | 2014-05-29 |
20140148504 | NOVEL USE OF FLAVONE-BASED COMPOUND - The present invention relates to a novel use of a flavone-based compound or a | 2014-05-29 |
20140148505 | METHODS AND COMPOSITIONS FOR PREDICTING DRUG RESPONSES - The present invention relates to methods and compositions for predicting drug responses. In particular, the present invention provides methods and compositions for determining individualized Warfarin dosages based on genotype of DNA polymorphisms and haplotypes derived from them in the VKORC1 gene. | 2014-05-29 |
20140148506 | DRUG ELATING SILICONE GEL SHEETING FOR WOUND HEALING AND SCAR REDUCTION - Provided are compositions of various silicone compounds loaded with active pharmaceutical agents, which are suitable for promoting the healing of skin wounds and the reduction or prevention of scarring. | 2014-05-29 |
20140148507 | PHARMACEUTICAL COMPOSITION AND SOLID GALENIC FORM HAVING A HIGH DRONEDARONE CONTENT, AND METHOD FOR PREPARING SAME - The present invention relates to pharmaceutical compositions to be used, in a solid galenic form, for oral administration, and primarily including dronedarone and/or at least one of the derivatives thereof, as well as to solid galenic forms manufactured as such from said compositions, preferably in the form of tablets or capsules. The present invention also relates to a method for preparing such solid galenic forms using a hot-melt process. | 2014-05-29 |
20140148508 | C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS - C3-functionalized-cyclopentanyltetrahydrofuranyl carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Compositions comprising the disclosed compound and methods of using the compounds and/or compositions for treating patients infected with HIV are also described. | 2014-05-29 |
20140148509 | STABILIZED ASCORBIC ACID SOLUTIONS; METHOD OF USE THEREOF; PROCESS FOR THEIR OBTENTION; AND COMPOSITIONS COMPRISING THE SAME - This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves sequential additions of ascorbic acid and ethoxydiglycol to a first solution of vitamin in water, which are followed by addition of propylene glycol. The stirring speed that occurs during the additions favors a process of micronization. Mild heating is used to achieve ascorbic acid concentrations equivalent to about 6% in 10% water or higher. | 2014-05-29 |
20140148510 | IMPROVED METHOD FOR PRODUCING EMULSIFIABLE PESTICIDE SOLUTIONS - The current invention provides a kit of parts for producing an emulsifiable pesticide solution comprising: (a) a water miscible organic solvent selected from the list of a glycol ether, a glycerol formal, dimethylsulfoxide, gamma-butyrolactone or mixtures thereof, (b) an alkoxylated alcohol with an average of 6 to 80 moles of ethylene oxide and 2 to 60 moles of propylene oxide per mole of alcohol; and (c) a pesticidal active ingredient. The invention further provides a composition for producing an emulsifiable pesticide solution, a method for producing such a composition and a method for treating an agricultural crop. In addition the invention provides some advantageous pesticidal compositions. | 2014-05-29 |
20140148511 | Novel Uses of Neuraminidase Inhibitors in Infectious Diseases - The present invention relates to methods of decreasing the infectivity, morbidity and rate of mortality, in treating diseases associated with a variety of pathogenic organisms, specifically diseases involving one or more pathogens that require neuraminidase as a virulence factor. In addition, the present invention uses biology based therapy to treat neuraminidase dependent infections or diseases dependent on sialic acid metabolism. | 2014-05-29 |
20140148512 | Soap capable of treating seborrheic keratoses, keratosis pilaris, keratoderma, and related conditions and methods of making and using - Embodiments include a soap capable of treating seborrheic keratoses, keratosis pilaris, keratoderma, and/or related conditions, comprising a soap base and additives including pumice and polyethylene. Embodiments further include a method of making and using the soap, comprising providing the soap base and the additives including pumice and polyethylene, mixing the soap base and the additives together, and forming the soap from the soap base and the additives. Embodiments also include a method of using the soap, comprising providing the soap comprising the soap base and additives including pumice and polyethylene, and placing the soap in rubbing contact with the seborrheic keratoses, keratosis pilaris, keratoderma, or related conditions. | 2014-05-29 |
20140148513 | SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME - The invention provides methods of inhibiting the development or progression of a thioesterase deficiency disorder in a mammal by the administration of a compound that functionally mimics the enzymatic activity of all thioesterases in mammals. Such thioesterase deficiency disorders include cancers and adult- or infant-neuronal ceroid lipofuscinoses (NCLs). The invention also provides small molecule mimics of thioesterases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds and methods of using the same. | 2014-05-29 |
20140148514 | POLY(ALKYLENE CO-ADIPATE TEREPHTHALATE) PREPARED FROM RECYCLED POLYETHYLENE TEREPHTHALATE HAVING LOW IMPURITY LEVELS - This disclosure relates to an aliphatic-aromatic copolyester of poly(butylene-co-adipate terephthalate) that is prepared from recycled polyethylene terephthalate in the presence of titanium catalyst and a phosphorous containing compound. The copolyester is contaminated with little or no ethylene glycol and/or isophthalic acid, which are artifacts of preparing the copolyester from recycled PET. Advantageously, because there is little or no contamination from ethylene glycol and/or isophthalic acid in the copolyester, there is essentially no depression in the material's melting temperature. | 2014-05-29 |
20140148515 | System and method for alleviating the appearance of scars and/or scar tissue - A system for alleviating the appearance of scar tissue, said system comprising a combination of two compounds; a first compound having properties that perform skin regeneration; and a second compound having properties that provide a physical barrier adapted to protect scar tissue by insulating it from ambient air while maintaining and protecting said first compound that is combined therewith. | 2014-05-29 |
20140148516 | WATER-IN-OIL TYPE EMULSION COSMETIC - The purpose of the present invention is to provide a water-in-oil type cosmetic which ensures emulsion stability in the case where a volatile hydrocarbon oil component is added, has excellent texture such as not leaving a greasy feeling, and is highly compatible with the skin. The present invention relates to a water-in-oil type emulsified cosmetic comprising:
| 2014-05-29 |
20140148517 | DISPERSION OF PARTICULATE CLUSTERS VIA THE RAPID VAPORIZATION OF INTERSTITIAL LIQUID - A process for dispersing agglomerates or clusters of particles utilizing pressure generated from volatilization of an interstitial liquid. More particularly, the method relates to infusing the particles with a first liquid, placing the infused particles in a second liquid or fluid having a higher boiling point than the first liquid and heating the composition to a temperature above the boiling point of the first liquid thereby resulting in breakage of the particles. Compositions including particles dispersed by interstitial liquid vaporization are also disclosed. | 2014-05-29 |
20140148518 | ENVIRONMENTALLY-FRIENDLY PASTE DISCHARGE AGENT FOR TEXTILE PRINTING AND PREPARATION METHOD THEREOF - The invention discloses an environmentally-friendly pasty discharge agent for textile printing and a method for preparing the environmentally-friendly pasty discharge agent. The environmentally-friendly pasty discharge agent for textile printing is formed by the following raw materials according to part by weight: decamethylcyclopentasiloxane: 30-60 parts; thiourea dioxide: 40-70 parts; surfactant: 1-3 parts; and glycerol: 3-6 parts. Decamethylcyclopentasiloxane is put into a ball mill, a surfactant is added into the ball mill to make the decamethylcyclopentasiloxane dispersed or dissolved uniformly and then stirred uniformly, and then thiourea dioxide is added into the ball mill and ground together for 1-3 hours. In the invention, the special liquid compound decamethylcyclopentasiloxane does not chemically react with the thiourea dioxide; in addition, it isolates the thiourea dioxide from outside water and air, thus increasing the stability of the thiourea dioxide. The discharge effect is excellent, the defects of low dissolvability, poor dispersion uniformity in the discharge paste, poor net permeability and insufficient discharge effect of the common thiourea dioxide as the discharge agent are overcome, and there is no influence on the touch of the discharged and printed textiles. | 2014-05-29 |
20140148519 | HYBRID PLANT FOR LIQUID FUEL PRODUCTION - A hybrid plant and method for producing liquid fuel product from hydrogen and carbon monoxide containing streams produced by gasifying solid carbonaceous feedstock and steam reforming of light fossil fuels. When a gasification unit in the hybrid plant is operating at reduced capacity or is not operational, oxygen that would have been used in the gasification unit is diverted to a light fossil fuel conversion unit containing an autothermal reformer to increase H | 2014-05-29 |
20140148520 | CARBON TO LIQUIDS SYSTEM AND METHOD OF OPERATION - A method of operating a carbon to liquids system is provided. The method includes receiving a flow of syngas and reacting, in a reactor, the syngas and a catalyst in a Fischer-Tropsch reaction to produce a product including steam, wherein the reactor includes a polymeric material that is configured to permit the permeation of the steam therethrough. The method also includes recycling the permeated steam to a vessel positioned upstream from the reactor. | 2014-05-29 |
20140148521 | METHOD FOR REMOVAL OF METAL IONS FROM AN AQUEOUS SOLUTION - The present invention relates to a method for removal of metal ions from an aqueous solution, which comprises contacting the aqueous solution with a phosphazene-formaldehyde resin as well as an ion exchange resin comprising a phosphazene-formaldehyde resin. | 2014-05-29 |
20140148522 | VULCANIZED RUBBER CONVERSION - Vulcanized rubber, for example from used tires, can be devulcanized to provide a reaction product that has similar rheological properties to the original un-vulcanized rubber. The vulcanized rubber is processed at a temperature that is less than a critical temperature of a solvent, such as water or water and alcohol. The process is carried out at a pressure that is higher than the vapour pressure of the solvent. | 2014-05-29 |
20140148523 | POROUS PARTICLES AND METHODS OF MAKING THEM - Porous particles can be prepared using an evaporative limited coalescence process in which one or more discrete cavities are stabilized within the continuous polymeric solid phase of the porous particles. The one or more discrete cavities have inner walls and are dispersed within the continuous polymeric solid phase. The porous particles further comprise a cavity stabilizing hydrocolloid on the inner walls of the one or more discrete cavities, and an amphiphilic (low HLB) block copolymer that is disposed at the interface of the discrete cavities and the continuous polymeric solid phase. | 2014-05-29 |
20140148524 | POLYURETHANE FOAM PANEL AND PRODUCTION METHOD FOR POLYURETHANE FOAM PANEL - A polyurethane foam panel, obtained by mixing a polyol composition comprising polyol compounds, and water as a blowing agent with a polyisocyanate component to react therewith, wherein the polyol compounds comprise a polyether polyol (A) which is a polymer made from an alkylene oxide and has an average functional group number of 2 to 4 and a weight-average molecular weight of 3000 to 8000, and a short glycol (B) having a molecular weight less than 250, the water is contained in an amount of 20 to 100 parts by weight for 100 parts by weight of the polyol compounds, and the thickness direction of the polyurethane foam panel is substantially perpendicular to the foamed direction of cells in the foam or at the time of mixing and reacting the polyol composition and the polyisocyanate component with each other, the isocyanate index of the component is 30 or less. | 2014-05-29 |
20140148525 | RADICAL POLYMERIZABLE COMPOSITION, CURED PRODUCT, AND PLASTIC LENS - There are provided a radical polymerizable composition having a low viscosity suitable for coating, a cured product obtained by curing the composition, the cured product having a high refractive index and high toughness and being not easily cracked or chipped when cutting, and a plastic lens obtained by curing the composition. A radical polymerizable composition includes phenylbenzyl(meth)acrylate (A), a urethane(meth)acrylate (X) having an aromatic ring in its molecular structure, and a radical polymerization initiator (Y) as essential components. | 2014-05-29 |
20140148526 | DENTAL BONDING AGENT AND COATING AGENT - The present disclosure provides a dental bonding agent which may comprise a composite resin containing an ingredient selected from acrylic resins, a primer comprising an amphiphile, and at least one phosphate ester, and a solvent. The dental bonding agent may be applied for resin restoration, prosthetic adhesion, enhancing adhesive strength between dentin and artificial post, and tooth coating. The present disclosure also provides a coating agent which may comprise a dental bonding agent as defined above, a pigment, and an inorganic filler. | 2014-05-29 |
20140148527 | AMINE FUNCTIONALIZED POLYMER - A macromolecule includes a functional group including imine functionality bonded to a polymer chain. Where desired, the functional group also can contain additional (e.g., amine and/or silane) functionality. The material can be provided by reacting a polymer including carbonyl functionality with a compound including a primary amino group. The functional group can interact with particulate filler such as, e.g., carbon black and silica. | 2014-05-29 |
20140148528 | IRRADIATED FLUOROPOLYMER ARTICLES HAVING LOW LEACHABLE FLUORIDE IONS - The invention relates to fluoropolymer articles that have been irradiated with at least 5 Kilo Gray of radiation, where the resulting articles have low levels of leachable or extractable fluoride ion. The low fluoride ion migration from the irradiated article is due to the presence of low levels of metalic salts or oxides in the fluoropolymer composition. The invention is especially useful for fluoropolymer articles in which the fluorpolymer layer contacts a biological or pharmaceutical fluid, and that are subjected to sterilization by irradiation. | 2014-05-29 |
20140148529 | CURABLE EPOXY RESIN COMPOSITION - A curable epoxy resin composition including a defined aromatic epoxy resin component and a defined latent catalyst system, and optionally further additives, the curable composition being a single epoxy resin composition having a prolonged pot life at a processing temperature within the range of 40° C. to 70° C., wherein: (a) the epoxy resin component is a compound of formula (I) in monomeric form or in a low polymeric form thereof, or is a mixture of such compounds: | 2014-05-29 |